ENTA - Earnings call transcript Q2 2020 | Enanta Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Second Quarter Financial Results Conference Call. [Operator Instructions] There will be a question-and-answer session at the end of the prepared remarks. [Operator Instructions]

I would now like to turn the call over to Jennifer Viera, Senior Director, Investor Relations. Thank you. ahead. go Please

Jennifer Viera

on and afternoon. operator, quarter everyone joining is for results Thank news thanks release this available and afternoon The issued second website. with us was you, this to our our financial fiscal

Luly, On Executive and Financial and Officer; Dr. Enanta's of Chief Chief other our President members the Mellett, senior is call Officer; today Jay Paul management team.

be expectations include our formal research pipeline remind and respect we involve that will control to our our remarks, you may certain our which and want with making we begin in periodic not undertake and statements, to the we and cause materially forward-looking of with all statements. Before to financial assumptions plans does from our forward-looking actual of beyond that reports development risks SEC. projections, during Form Enanta to these obligation is statements description call. most and XX-Q filed made and could this recent our with other results any update differ A any risks developments these which

now over and to Dr. Jay? CEO. Jay Luly, President I'd the to turn call like

Jay Luly

I'd Jennifer. during to you, pandemic. the everyone. are acknowledge like times afternoon, Good to COVID-XX take a experiencing the extraordinary Thank moment we

safety who through for the affected. who worst we weeks move caregivers, navigate are well-being with we we this are great it our And and sacrifices The will grateful of paramount as making to are forward. and are prioritize thoughts responders and Our good, continue common the we as those of efforts employees others heroic directly first many for is crisis. the of

execute In uncertainty, to and our commitment continuous business during and our their for great the has allowed to core This our will upheaval therapies I plans expertise resolve operations on these threats. unmet needs. the and crisis to our possible unwavering their want our the employees of thank other global last given Enanta business And for that us and weeks. several period to and enable emerging milestone diseases to mission a for momentum maintain virology us circumstances. dedication to respiratory goals novel part COVID-XX, advance best viral positions healthcare solution of in extent both has strengthened be to

start respiratory pipeline, disease the end, namely, newest COVID-XX. by virus highlighting in our I'll program that To

in with announced candidates we to COVID-XX. track As you know, patients that drug of a and virology discover infected record our program on we the mid-March, initiated Based antiviral treatment for in direct-acting we taking leveraging our COVID-XX COVID-XX. potential capabilities discover can a believe and a in for respiratory competencies approach our diseases, treatment experience for two-pronged are core we said, we to our our leverage proven That

efforts. Not We'll coming against only candidates finding expertise in Among virus, potential We is to other and begin virologists COVID-XX. well. continue compound Discovery interest, and activity to from our a in direct-acting but Not to for inhibitors. candidates. These this to the protease direct-acting compounds focus endeavor, quarters. what are simple antivirals. ultimately for discover an it which testing what involves us efforts using our background library leads SARS-CoV-X initial are this our treat COVID-XX does discovery and are Enanta are antiviral mechanisms mobilized we update mechanisms the does chemists new and our antiviral we program, of

is morbidity RSV. currently compromised severe the immune and infants, with safe turn respiratory virus now respiratory which RSV To there significant infection therapy. effective EDP-XXX remind will associated for and and a syncytial a program or condition in I no mortality and to respiratory our everyone, lead for virus adults, is elderly

hospitalized this about year older the five, XX,XXX for and Each approximately XXX,XXX United from XX,XXX die are in States, and infection. below age respiratory children adults RSV,

Southern Xb study, Hemisphere. completed are track move into the on the and with our as season plans States to United have RSV Phase We RSVP the in known

season. the is that American fall we're ready winter of keeping in uncertainty also RSV in created the Given for and spread reactivation North by sites region, our COVID-XX

number We are substantial planning add in of to sites Europe.

would If third we the of can complete calendar enrollment data we next expect winter, Northern quarter the in have to study this for XXXX. in Hemisphere

secondary reminder, the is a double-blind RSV RSVP objective EDP-XXX infection has years, is clinical be The protocol to placebo course to age symptoms of exclude study. effect by either will the up EDP-XXX XX study designed subjects five to the Obviously, are approximately XX impact patient a primary the of of over RSVP, EDP-XXX of COVID-XX currently As as And COVID-XX randomized evaluate to do eligible study or RSV. any of period. this a of endpoint. pandemic process the our presence efficacy assessment progression disease placebo-controlled for we on XX of to of in receive randomized on Antiviral to of days. milligrams in evaluated an enroll any measured XX of modifying testing with the observation the days potentially study respiratory

we've it's our Cepheid collaborate which at now additional machines getting the of testing test B process We A, Southern in American RSV, are These the continue is machines We're PCR with sites. North the from real-time to that used for COVID-XX. machines, flu flu can hemisphere set and out sites.

transplant II RSVP adult also with one this of and two pediatric by one We're in the end to in studies, track Phase on patients initiate concurrent the study. year additional patients

will RSV Fortunately, in as hope illness a in respiratory effects patients winter their take on ill for willing the the today, be condition, health in have to the alert And high even doctor, be to Northern would study. participate parents transplant of and Hemisphere. given if anticipate as children clinical adults. continues And COVID-XX on children not will been continue season pandemic appears immune into suppressed to we the to we the severe it

we more upon for how later However, fall. study the recognize in potentially depending pandemic there challenges the the are moves transplant

of that respiratory young and the infections third for year. beginning pathogen upper respiratory the portfolio, human as hMPV we introduced as asthma well metapneumovirus, COPD, discovery in is and hMPV Regarding immunocompromised and in in our as tract a known lower the our children at elderly patients. the also virus program causes

children of challenge of age common age airway also XXX,XXX hospitalizations cause less that fact, infection for year. years in the second in with accounts more presents group lower this significant a in the elderly five most health each In than hospitalizations more behind RSV immunocompromised hMPV than XX,XXX than it's annually. and individuals

current first We continue our our of to this perform toward optimization identifying as we candidate leads hMPV work nanomolar indication. clinical for inhibitor

of on portfolio our to liver-related move of now focused the treatment conditions. products, I'll

further let two Xa/Xb of America, quarter. HBV month are patients Last North study in EDP-XXX core you in in our update hepatitis class stage II nuc-suppressed First, this our we clinical recruitment of novel part our initiated Phase earlier in me inhibitor. that on we pausing EDP-XXX, program with which B HBV announced

drug enrollment sites XX for the dosed open. depending study to among circumstances total of to within with We next dose infection with of patients days. Nuc-suppressed are this reverse are We're subjects of enroll months, to the that evaluating chronic cohorts being current with resume around is able upon XX couple and nucleoside plan suppressed transcriptase treatment. hoping clinical a refers our to enough three HBV of care. standard regularly study whether The escalating

during and is patients not with trials trials the regarding of Given of conducting the FDA of nor pandemic disease clinical participants and short clinical guidance chronic during safety integrity on in COVID-XX practicable data its the trial conduct the recommended. pandemic, trial emphasis term

guidance to we'll follow to to such, continue it when the resume As determine study. safe regulatory is

levels Xb We're the who viremic. on are track to virus and initiate also quarter patients Phase therapy to referred who as of on pleased not in high have to be our their study HBV who in blood, this are also

about than optimistic this those in better a in viremic is COVID-XX Western unmet there sites given Hong are that where to be appears for patients, and in countries, and Taiwan, control large treatment. need are moving We HPV our forward study under Kong where areas

on study HBV on As impact assess therapies. a this EDP-XXX reminder, load patients viral the not will other in of

are study around data year-end. are about because We we which next we targeting readout, that produce expect for will clinical excited our this

safety, to But endpoint from of XX-week, at EDP-XXX, primary me from efficacy a first, in our we with PBC of PBC, and farnesoid Xa steatohepatitis without cholangitis at I'll with in randomized, acid. our the study on or or was XX. week INTREPID to in let of study placebo-controlled both non-alcoholic ursodeoxycholic XX% ALP ALP, in focus agonist pharmacokinetics study. our primary or Phase double-blind, X or normalization evaluating subjects today, was The now Earlier EDP-XXX to PBC. receptor the and announced evaluate least NASH. tolerability, an development pre-treatment move value, INTREPID subjects the reduction inadequate or with of for response biliary FXR efforts data proportion

compared respectively, rates, milligrams higher in ALP treatment to the with These In were significant. placebo. XX% resulted and in placebo or of EDP-XXX while X X.X not XX% responses, intent-to-treat analysis, and XX% statistically numerically than ITT response milligrams

with at X.X arms study an However, XX% analysis respectively, milligram in and in treatment in proportions showed The no and completed to of XX%, missing compared subjects the significant week XX% X statistically value placebo. ALP rates milligram of the of responders response XX. who

were observed the of significant reductions baseline AST key these baseline percent of key EDP-XXX the tolerability enzymes evaluate both in EDP-XXX. biomarkers placebo. week-XX Data amounts placebo secondary as or EDP-XXX of arms statistically these full to the population to from Key and ALT, was showed in GGT. A in from milligrams ITT liver the objectives statistically at X and in milligram X.X also well safety to changes at difference as biomarkers compared from significant absolute compared changes of

safety, the adverse with TEAEs observed symptoms, subjects milligram to placebo more or tolerated the common discontinuation TEAEs with treatment-emergent than In EDP-XXX for weeks. majority being to milligram X% incidence XX These safety are X% moderate. TEAEs the the treatment due EDP-XXX insomnia. in of events EDP-XXX with consistent INTREPID for XX% and for was gastrointestinal-related subjects was treatment treatment up pruritus, and XXX in to included group. group profile well of most treatment exposed X the across The group, for X.X headache terms of generally PBC, approximately The pruritus mild to

analysis, meet for for data we the While not use help to endpoint and ITT our of the to did NASH. inform EDP-XXX plan these primary we development PBC

to in ARGON-X study that of X significant an and profile NASH target is believe encouraged are of of number that We the pruritus, dose we significantly tolerability could responders X.X that milligrams our to comparable of X while the milligrams X.X and statistically engagement. in intermediate patients. dose on Specifically, terms milligram of having for still NASH key tolerability see of achieve dose biomarkers the or in the helpful PBC. milligram without reducing achieve X.X milligrams we doses efficacy X milligrams of potentially plan this ALP in use We information the in and effects lower better

deck slide we on our the For more will see that on INTREPID information this the call. study, please website after post

to selection and generic and disease conducting components are to be where PBC, with potential focus like than there in approved designed an further for see Rather studies is agonist with We some NASH, give our efforts on EDP-XXX NASH. drug fibrates benefit dose EDP-XXX FXR to showing second-line as agonists benefit which EDP-XXX maximum already a a therapy, for the disease We have studies. intend to future FXR important of combinations which patients.

NASH. NASH program, randomized, with XXX evaluating we and Xb biopsy-proven ARGON-X, on our XX-week a study remain placebo-controlled in double-blind, At EDP-XXX approximately Phase focused subjects

the this While March, ready study did constraints as schedule to ongoing the and clinical having due as of in sites. to in to pause ARGON-X decided on resource trial recruitment pandemic. the dosing were COVID-XX trial in well mind begin our We clinical participants we dosing safety to we

the generate engagement reminder, milligrams, use doses terms interim balanced more with We a efficacy we ARGON-X and/or of to primary of fibrosis. NASH worsening resolution As be XX-week ARGON-X quickly will plan information fibrosis tolerability. and X.X strong in milligrams mechanisms will improvement other selected in for to X target NASH include and NASH. dose endpoint of without to provide in of worsening and of a profile without potential combinations a analysis which

for the open it tissue-targeting readout compelling is our third of of developing and to compared other in to EDP-XXX, in initiate in in to the Also resume able to our of in high trial the at of context potency have about next data which up within the demonstrate we quarter, Phase the that produce the the COVID-XX our in couple XXXX. whether clinical we the a NASH previously Subject follow-on the plan the FXR COVID-XX, be pandemic. context study agonists would sites depending trial initiate FXR Europe likely now in shared of we'll able program, are candidate. we development. in second to a I this months, preclinical trial a are EDP-XXX excited to site that the that later We're of hopeful study study of volunteer quarter upon this enough determination characteristics EDP-XXX We're safe healthy

I treatments would a several developed are C moment limiting MAVYRET comment period. where AbbVie access adversely hepatitis pandemic new non-emergency, hospital-based pipeline, experiencing for a our COVID-XX in it prolonged If with like affect Beyond take of AbbVie. treatment to this non recently international to period, announced on we expect that markets COVID-XX hospitals the to that AbbVie's in our to MAVYRET, continues patients. sales during for volumes is patient collaboration lower

by other periods, there However, sales is we also that no treatment. since expect than that materially likely infections to shift subsequent expectation existing those decline eventual will will

guided HCV its has to in to guidelines be expects for C recommend that $X.X be billion. XX the virus. also now it to sales noting XX CDC that We adults April that issued approximately that now all tested Also XXXX AbbVie calendar ages XXXX, note worth hepatitis

ongoing ahead novel of combination the pipeline our market respiratory and the of to viruses our In few on unusual we effects have allows diseases. our opportunities key remains pipeline don't Despite business Enanta currently to closing, sheet like liver which well royalty strong challenging therapies a to to backdrop advance wholly-owned COVID-XX, and I'd plans balance for positioned The of a revenue independent capitalize capital growing and could execute of takeaways. us our and advance conditions. on point expect, to

We on-track milestones. several with are

our First, hepatitis begin of slated this Xb quarter. B is to EDP-XXX Phase viremic in patients study

Second, next in of our first initiate for are quarter. we EDP-XXX to planning human study NASH

pediatric patients are Regarding fourth patients begin our RSV program, adult track our and two on transplant to in in still Phase studies quarter. II the

the add in ready keeping hemisphere, we Europe. planning fall RSV are sites and are while for upcoming Northern our later American RSVP study number substantial for also in we the of sites to advancing Finally, year, season. Southern And winter this our reactivation a

Assuming in we top to very XXXX. solid have quarter place. Hemisphere next several would Northern calendar position in Overall, we line can third are the with expect complete the the in study opportunities We season. data in of a RSVP

over With will call discuss to that, I now Paul? financials to Paul turn quarter. the the for our

Paul Mellett

September we XXth XX, to fiscal reporting results quarter on Jay. fiscal you, everyone like would for Thank I year remind schedule. Today, that second March XXXX. reports Enanta are a our ended

market same consisted quarter, For revenue on entirely This total have it's AbbVie and revenue for sales of $XX.X due within select Managed Medicaid AbbVie's HCV pricing volumes XXXX. revenue was million product were of increased royalty global and markets that earned competition in international and the $XX.X in sales. the US HCV and treated patient total segment. stated decline compares period share to affecting the a lower million to

been rate calculated historically total reported a X.X% have approximately on XX% product MAVIRET royalty which contractual revenue discounts the of AbbVie's at and sales. Royalty adjustments HCV for was quarter XX% after for certain sales rebates, of of

for tier fiscal calculated are royalties the calendar calculated fiscal Therefore, year on a year. reminder, at our March royalties ending basis. second for quarter XX our a our royalty lowest As rate are

You schedule can our Form XX-K. XXXX review our in royalty tier

Moving on expenses. our to

decrease of in in the three the totaled expense period clinical due costs to XX, the March ended the for Phase $XX.X same PBC. studies compared was to due development NASH research prior For in year million, and decrease months primarily to The a XXXX, expenses XXXX. and $XX.X II for trial timing million in

to was General $X.X in $X.X million quarter comparable the million the quarter and administrative for for compared XXXX. expense

during prior benefit driven award-related increased benefit XX, an for to year, income of months the loss activity a XXXX. stock the in income income tax March an to development the tax ended period an by compared recorded and million income tax despite of recorded $X.X employee current and same benefit $X.X tax we our for an three deductions In quarter. recorded research tax pre-tax XXXX quarter, million reporting from Enanta credits. the In benefit the tax Enanta pretax due income

a Net in $X.XX $X diluted diluted corresponding share $X.XX compared ended months of income XX, to period the or of loss net $X.X March XXXX. common per common or for per the million, million, loss was XXXX three share, for

Enanta year-end $XX securities, and increase approximately with cash in XXXX the million million. marketable balance an of ended quarter fiscal million our $XXX of approximately from $XXX

foreseeable We resources royalty expect cash our future. sufficient continuing revenue cash to that these as for as well the will our requirements be meet anticipated

available Further release will our financial and press be quarterly details on are report our available Form in when XX-Q in filed.

like turn to up for call open the to back Operator? and now questions. I'd the operator lines the

Operator

line first of Your Roth from Rahimi Partners. [Operator Capital question the Yasmeen Instructions] is with

Yasmeen Rahimi

Hi, team. for all you. for updates. Two questions the you Thank

shed that also placebo have The reason more was first study be light response patients we than had you higher you hoped that missed us. recruited kindly regards one could noticed endpoint? its maybe any may severe for the INTREPID some helpful color in can PBC primary we could that there have Is is, on Any on why contribute for. or that could the

then can And taking on so just been update much you thank our against was has ago? the are in an progress weeks And made announcement a your question. to you is, second antiviral few for since How regards -- SARS-CoV-X? you announcement question us made much give the where development

Jay Luly

take about the Thanks, the Yas. to COVID INTREPID This is Nathalie Why Jay. I'll question, question. ask I don't and talk

and up substantially really and clear went in than only March side have paid camel. its coronavirus was that and and away. kind SARSX who burned It COVID sort to to attention which you proximity the much people start timeframe of So different pick-up it hadn't regions but our on of pops close know, things, the MERS then, very watching still we announced we now own coronaviruses, pretty on it to that in after other the as of program in became out

So COVID behaving in to But really [Phonetic] global very be of we now, it isn't differently. a seems as a know threat. sort Spain all

So key have have things from we ago been multipronged first mobilized the getting team testing. our weeks just approach as our and approach, and just some a library for taking as several -- up ready is

forth. we've virus, each within we Within of over multiple mechanisms. of different structural and we As viruses on worked you on each often have of know, Against each different molecules and mechanism, different years. so virus lots the worked classes lots

for so And library types. pretty different got in robust we've tumor a many testing molecules selection for

external certainly still through would There we've So, SARS-CoV-X, that. -- I going backlog who say that still at but going the of we're testing it's a these And handle lot it's effort. required facilities can on. for BL-X conditions is mobilized of a

we that's direct of if like unpack in might safe, highly time. and activity it, might that we do convenient where on of to with also chemical we identify saves taking So this potent, to bit certain a a it point then figure treatment. launching learn interesting ideally little the much to targeted then use But sort viruses -- targets out all hope passive virus approach, leaving an about us we're case not we be. a where of more we find drugs optimize do highly our chance vulnerabilities And key for anything just we oral

you a more our surprise C is probably biology not will, multiple it that has started initiative -- and has if legacy targets. different based chemistry Among and hepatitis on drug protease, them, on that's like classical, we ensued. started discovery So and

Nathalie, on weeks number on report [Phonetic] but breaking any under short sort COVID updates we the difficult constraints and to mobilized as don't you to quarter, results effort. a of have year teams of we'll this want comment the just So been do the backdrop. highly INTREPID? But giving of again it's the are be progresses. So,

Nathalie Adda

Yasmeen. for your Thank Sure. you question,

point maybe The up use bar. was the you endpoint, which choice weeks of as a endpoint few patients So, I a reduction, consideration can study high primary proof-of-concept out. with setting of than the you as of XX% can we for XX proportion notice, more

that at So reduction a look I to change we over significant. was time statistically If think important we that. for ALP, time it's just notice nice over the had

the that consideration recruitment, we we the study, There power endpoint of back believe probably that lack meet XX here. I that a [indiscernible] I the that we that on missing to point comment a because So number had figure that subject. to can there few could help of the sufficient the data decided is endpoint us is of while with

point to because we sample the effect that that fact calculated placebo You and are a contributed was think a we our we absolutely right the fact small And of have we size little the than that discontinuation I have consideration rate other also to power. endpoint. sample higher higher could other missing bit the a That have out studies. anticipated in size

nice we far expressing the size think randomization From given a and difference standpoint, one X, have And the small X difference a we a placebo. can as had numerical subject sample even ratio for significant make as from huge the I to value. that P

the So I entire further and what be obviously to to more the looking result. can this today. color hope to is We data I share bring we'll set,

Yasmeen Rahimi

you, you, and color. Thank the Jay, Nathalie, for thank

Jay Luly

You're welcome.

Operator

question from Baird. with line next of is Brian Skorney Your the

Unidentified Analyst

Hi, have were Luke the multi-patients patients. the outlook -- that Thanks. programs mild taking road with the Thanks this on COVID [ph] call. level wondering, development entering and in how planned frames there at severe prophylactic, other and on for on it future? clinical How Thanks to clinical Brian. is looking going? for severity We for the does your moderate is

Jay Luly

indication for Yes, to confront. people I this think certainly like any indication, new over is be It's -- evolve going a any to new to it's time. going --

why doing that lower airway have look regions in an get it, on other makes antiviral not good lot going been early things of sense. And at We lot inflammation disease is late airway tested can infection, people cytokine in storms ideal. people stage of an days to-date. certainly crisis asking mode, any of By in of late. late complications, treated and are to ones including the a disease, and that see awful stages too perhaps [Phonetic] has disease it's a then, all COVID we upper are progressed So, into getting from certainly, at

you're mode. You don't the have anything else when crisis in

waiting kinds for of So all while for possibility do. can vaccines, the products about people come other along, you to waiting are more that's of optimized

We're looking not they're into obviously actually discovery their not further patients in or toward participating development. And in when entering vaccine progressed we're disease.

they thinking if RSV. come ultimately, I of can lights little ideally walk you our get would diagnostic direction. imagine in a another go. they bit up in will while a headed And treat a perhaps doing another eventually direction; in like then it been for RSV, you in that Obviously, not it a available. sort symptomatic tested. get into toward about is few clinic, is a where [Indecipherable] be they think if And state to now [Phonetic] RSVP treat for a of this lights-up you There one RSVP patients if rapid to it flu, where COVID, up we've days, unlike study sort in, it the they really If treat may study. present we're -- if great lights It's test direction. do in our there

to. off we terms ultimately -- able are of that others to aspiration can think we so an really we an would that's But COVID we're if before a ways and probably a pretty where And be way. impact I in make managed like [Phonetic]

respiratory getting and human likely want do the of the change this think and about them And you course RSV, on while been saying really we've for drug quite viral to early. infections, best getting in diagnosed I if it. a the to way early it's So, that's most the longer patients all

COVID, the think just crisis appreciated hopefully the plateau get at a stable I probably has with and course better the to management the in end we'll a managing patient disease. the the challenge shift of where to also back direction. more been that's now of can date testing But

Unidentified Analyst

Thank so you much. Okay.

Jay Luly

You're welcome.

Operator

from Your with Tewari line is the of next Instructions] [Operator Research. question Wolfe Akash

Akash Tewari

Hi.

any And theoretical combo consider approach or think resistance recently to protease are in N-inhibitor using kind a pros and this RSV, targeting of think you an on potential results with J&J ever the later L effects a or synergistic some or minimal of some would an to trials? both as other to And and your First to we cons and in saw due would those What do efficacy? one CX-L approaches do and assessing you Pfizer combo in protease MoA. safety Enanta's compare identified well regards a NUCs. F-inhibitor affinity. as like to be inhibitors, approach know COVID success monotherapy some combat to of ReViral How an secondly, you coronavirus antiviral inhibitor then, versus with history of the we would MoAs

Jay Luly

Sure.

first your take me first. let So question

working was NUCs think, the the approach. very our for approach went a I or started So favor [Phonetic]. entry of so-called in we the an f the nucleoprotein -- or that EDP-XXX, approach have slate the We of -- one we had clean in or beginning side to our and we're sort with pushed of RSV that inhibitors other on mechanisms. The actually with mechanism program, that initially we fusion could case, we

protein against prophylaxis great to a can F that time in So antibody targeted of be monoclonal where before this set monoclonal And people, obviously, case there deal and a We makes with be in sense on the got approach present drug block excited up synagis, entry. of that. to the the virus. antibody think it's with first perfectly

time pretty infection late may deal you're ongoing infection The if virus that of is in from That time of you've has a involvement. a particularly little infection. good getting they the cells, fusion progress you inhibitors a active bit viral got fear of have for be already impact, had if lot where said, maximum as an entered patients

out EDP-XXX molecule a turns super inhibitor of very So And a has it we resistance. N targeted that is resistance, out want reasons using barrier possibility this to and the barrier. it high use mechanism an to and a the thwart our non-fusion to approach that many that turns of combination you high

So -- all virology and those the we've demonstrated that along data preclinically lines. and have shown

EDP-XXX I fusion in the low actually will molecule fusion our in by hand incredibly resistance. inhibitor, which like inhibitors whereas why contrast see could to way an barrier So, the have to

sense makes inhibitor. resistance have else And you a with approach you have quickly been can popping patients so very fusion virologic to of dosed mutations up in to it, a perspective, in because fusion it see lab to a and good deal add something who inhibitor from if very readily the try

So N inhibitor not a inhibitor. fusion need to N like an would I say more something an a likely but need fusion may

can't to that we a Of with even than we rule other such on might if could an seeing RSV, optimizing already we ever one good are we've even efficacy see greater we higher that added of is or we're as course, even a we a that no in levels. end, might mechanism marry better That's with be than of that seen. out to N to find something And N possibility. a it on well approaches may that that that to benefit efficacy terms working else N

that's So that. on our thought

that target SARS this. approaches In identified, of is be has think we already could -- terms But lots PI about direct-acting well, going in for antivirals like of ways that well vulnerability that protease after you as or the important mentioned, anyway, virus. There's an could the has here. been I've likely

makes us Enanta targets and others those. a is good we like for deal of not on So I pretty working inhibitor just will that. ignore it protease shop suspect and a great sense be to

have -- have are know. you can not necessarily NUCs they as uninteresting. liabilities They

optimization the good understanding say, our such pharmacokinetics profile how have maybe a of of of interest question good are that antiviral you just antiviral really the that I would safety having this so direct-acting to addition taking. stage required But there. And is in of of effect because any an really and a profile early there, virus fine-tuning targets the it's

Akash Tewari

Awesome. Thank you.

Jay Luly

You're welcome.

Operator

turn no I over Jennifer. will There further to are call the back questions.

Jennifer Viera

us you, Thank today. everyone, for joining

If you a give questions, have call free feel office. additional to care. us in Take the

Operator

Ladies this for gentlemen, participating. and today's conference you call. concludes Thank

now may You disconnect.

Enanta Pharmaceuticals (ENTA) 7 May 202020 Q2 Earnings call transcript